Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024530 (malaria)
 44,886 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Six diseases are the targets of the vaccine development program in India. The project involves 12 national research institutions and two private companies, Indian Immunologicals and Bharat Biotech, which are both based in Hyderabad, India. Targets of the program are AIDS, cholera, Japanese encephalitis, malaria, rabies, and tuberculosis. In a report in the journal Nature Medicine, K. S. Jayaraman notes that a single agency--the Department of Biotechnology (DBT)--will oversee the project. According to Jayaraman, DBT secretary Manju Sharma predicts the deployment of cholera and rabies vaccines by the year 2002. An oral recombinant cholera vaccine recently proved safe in Phase I trials at the Institute of Microbial Technology, Chandigart, and a promising DNA vaccine for rabies is in late preclinical development at the Indian Institute of Science, Bangalore. The AIDS vaccine initiative, underway at the All India Institute of Medical Sciences, New Delhi, will use a poxvirus construct expressing HIV-I subtype C, the strain most prevalent on the Indian subcontinent. N. K. Vinayak, head of the DBT medical division, told Jayaraman that the HIV vaccine would be ready for animal studies in a year. Funding for the program seems small by Western standards: $4 million over 3 years.
 ...
PMID:India embarks on vaccine-development scheme. 1234 53

Long distance journeys are more and more frequent. Beside malaria prophylaxis, the general practitioner shall consider several points. Vaccinations against tetanus, diphtheria and (for a few years at least) polio should be done every ten years. Hepatitis A vaccine shall often be done (with > 20 years protection) but typhoid fever vaccine shall be limited to adventurous and/or long stays. Yellow fever vaccine (10 years validity) is only administrated in specialised centers; this is the only mandatory vaccine for certain african or south american countries. In certain instances, one shall consider vaccination against hepatitis B, meningococcal meningitis or, less often, against rabies, central european or japanese encephalitis. The vaccine against cholera (numerous side effects and poor efficacy) is no more available.
 ...
PMID:[Vaccinations for the traveller]. 1242 42

Long distance journeys are more and more frequent. Beside malaria prophylaxis, the general practitioner shall consider several points. Vaccinations against tetanus, diphtheria and (for a few years at least) polio should be done every ten years. Hepatitis A vaccine shall often be done (with > 20 years protection) but typhoid fever vaccine shall be limited to advanturous and/or long stays. Yellow fever vaccine (10 years validity) is only administrated in specialised centers; this is the only mandatory vaccine for certain african or south american countries. In certains instances, one shall consider vaccination against hepatitis B, meningococcal meningitis or, less often, against rabies, central european or japanese encephalitis. The vaccine against cholera (numerous side effects and poor efficacy) is no more available.
 ...
PMID:[Vaccinations for the traveler]. 1259 70

Travel is associated with a number of neurological disorders that can be divided into two categories: (1) Neurological infections including encephalitides, neurotuberculosis, neurobrucellosis, cysticercosis and trichinosis. Some of these disorders can be prevented by vaccinations, such as Japanese B encephalitis and rabies, some by the use of insect repellents and some by avoiding raw milk products and undercooked meat. (2) Non-infective neurological disorders, such as acute mountain sickness and high altitude cerebral oedema, problems occurring during air travel such as syncope, seizures, strokes, nerve compression, barotrauma and vertigo, motion sickness and foodborne neurotoxic disorders such as ciguatera, shellfish poisoning and intoxication by cassava. This group of diseases and disorders could be prevented if the traveller knows about them, applies simple physiological rules, takes some specific medications and knows how to avoid intoxications in certain geographical areas. Meningococcal meningitis, malaria and jet lag syndrome are extensively discussed in other articles of this issue. The discussion in this paper will be limited to the other disorders.
 ...
PMID:Neurological disorders and travel. 1261 85

The article focuses on the Indian initiative of making kits for diagnosis of various infectious and non-infectious diseases as well as reproductive hormones and hormones in various other endocrine disorders. Indigenous diagnostic kits for the detection of various infections such as filariasis, typhoid, amebiasis, Japanese encephalitis, hepatitis, HIV, dengue, leishmaniasis, malaria, rabies, toxoplasmosis, rotavirus, and group A streptococci have been developed. Agreements to transfer the know-how of some of these leads to industries have been signed. The know-how of enzyme-linked immunosorbent assay (ELISA) for detection of hepatitis C has been successfully transferred to industry and is being commercially produced. For detection of HIV-1 and HIV-2, indigenous diagnostic kits based on three different formats, namely ELISA, Western blot and rapid test have been developed and are being commercially produced by Indian industries. The factors influencing the successful transfer of laboratory-scale diagnostic assays from academia to industry and their commercial exploitation have been discussed. Indian scientists have made seminal contributions in exploring the possibility to develop an effective and safe contraceptive vaccine to control the increasing human population of India. Achieving contraception by means of vaccine is a novel approach, which entails generation of a specific antibody response against antigens critically involved in the process of mammalian reproduction. In India, three major programs on contraceptive vaccines based on the beta-subunit of human chorionic gonadotrophin ((beta)hCG) for women, ovine follicle stimulating hormone (oFSH) for men, and riboflavin carrier protein for both males and females have been initiated. The work at the National Institute of Immunology, New Delhi on contraceptive vaccine for women, based on (beta)hCG, has demonstrated, for the first time, that it is feasible to regulate fertility by such an approach. Basic research being carried out to achieve immunocontraception by interfering at sperm-oocyte interaction level has been briefly discussed. These developments are still at the research stage. In addition to advances in the area of contraceptive vaccines, a non-steroidal contraceptive oral pill has been developed by Central Drug Research Institute, Lucknow, commercially produced by two Indian pharmaceutical companies and has been incorporated in the National Family Welfare Program. Another interesting approach for fertility regulation in male has been developed in India, which involves vas occlusion with styrene maleic anhydride (SMA) and is currently undergoing clinical trials in human subjects.
 ...
PMID:Status of immunodiagnosis and immunocontraceptive vaccines in India. 1293 96

The data on the sanitary and epidemiological situation in the Southern Federal District are presented. The analysis of morbidity in tuberculosis, measles, HIV infection, viral hepatitis A, typhoid fever, cholera and quarantine infections, Crimean hemorrhagic fever, West Nile fever, rabies, malaria has been carried out. Special attention has been given to "new and newly returning infections", and among them to the spread of SARS ("atypical pneumonia"). The role of regional epidemiological safety programs, in particular such program as "The prophylaxis of quarantine and natural focal infections and the sanitary protection of the territory of the Southern Federal District of the Russian Federation from the import and spread infectious diseases in 2003-2005", has been substantiated.
 ...
PMID:[On the epidemiological situation in quarantine, natural focal and other infections on the territory of the Southern Federal District]. 1534 45

Travel Medicine is a rapidly evolving field of medicine that is becoming ever more important in this era of globalization. Traditionally, medical preparation for individuals traveling to countries outside the United States has focused on traveler's diarrhea prevention and treatment, malaria prevention, and travel vaccination. Now, other concerns such as travel safety must also be considered. New developments in the area of travel medicine include the use of azithromycin instead of quinolones for diarrhea acquired in Southeast Asia. Azithromycin may also be the best option for children and patients who cannot take quinolones regardless of destination. In addition, rifaximin, a non-absorbable antibiotic, has recently been marketed for traveler's diarrhea. The best malaria prophylaxis options currently include atovaquone-proguanil (Malarone) in addition to chloroquine, mefloquine, and doxycycline. Hepatitis A is the most important travel vaccine, and a new combined hepatitis A and B vaccine (Twinrix) is useful for travelers needing protection against both types of hepatitis. A vaccine for typhoid is now available in either oral or injectable versions. Other important vaccines to consider when traveling internationally are those for Japanese encephalitis, influenza, meningitis, rabies, varicella and yellow fever vaccines. These may be warranted depending on duration of travel and destination risk.
 ...
PMID:Travel medicine 2005. 1577 61

We report the first trial of candidate malaria vaccine antigen FMP1, a 42kDa fragment from the C-terminus of merozoite surface protein-1 (MSP-1) from the 3D7 strain of Plasmodium falciparum, in an endemic area. Forty adult male and female residents of western Kenya were enrolled to receive 3 doses of either FMP1/AS02A or Imovax rabies vaccine by intra-deltoid injection on a 0, 1, 2 month schedule. Thirty-seven volunteers received all three immunizations and 38 completed the 12-month evaluation period. Slightly more recipients of the FMP1/AS02A vaccine experienced any instance of pain at 24 h post-immunization than in the Imovax group (95% versus 65%), but otherwise the two vaccines were equally safe and well-tolerated. Baseline antibody levels were high in both groups and were boosted in the FMP1/AS02A group. Longitudinal models revealed a highly significant difference between groups for both the average post-baseline antibody responses to MSP-1(42) (F1,335=13.16; P<0.001) and the Day 90 responses to MSP-1(42) (F1,335=16.69; P<0.001). The FMP1/AS02A vaccine is safe and immunogenic in adults and should progress to safety testing in children at greatest risk of malaria.
 ...
PMID:Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya. 1638 79

The feasibility of using a sensitive polymerase chain reaction (PCR) to evaluate malaria vaccines in small group sizes was tested in 102 adult Gambian volunteers who received either the malaria vaccine regimen FP9 ME-TRAP/MVA ME-TRAP or rabies vaccine. All volunteers received the antimalarial drugs primaquine and Lapdap plus artesunate to eliminate malaria parasites. Volunteers in a further group received an additional single treatment with sulfadoxine-pyrimethamine (SP) to prevent new infections. There was substantially lower T-cell immunogenicity than in previous trials with this vaccine regimen and no protection against infection in the malaria vaccine group. Using the primary endpoint of 20 parasites per mL, no difference was found in the prevalence of low-level infections in volunteers who received SP compared with those who did not, indicating that SP did not reduce the incidence of very low-density infection. However, SP markedly reduced the incidence of higher density infections. These findings support the feasibility and potential of this approach to screen pre-erythrocytic vaccines for efficacy against infection in small numbers of vaccinees in endemic areas.
 ...
PMID:Low-level malaria infections detected by a sensitive polymerase chain reaction assay and use of this technique in the evaluation of malaria vaccines in an endemic area. 1736 Aug 72

In a malaria-endemic area of Africa, rabies was an important cause of fatal central nervous system infection, responsible for 14 (10.5%) of 133 cases. Four patients had unusual clinical manifestations, and rabies was only diagnosed postmortem. Three (11.5%) of 26 fatal cases originally attributed to cerebral malaria were due to rabies.
 ...
PMID:Rabies encephalitis in malaria-endemic area, Malawi, Africa. 1737 May 29


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>